The New Role of Blood Tests in Helping to Diagnose Alzheimer’s Disease
Lori La Bey talks with Dr. Joel Braunstein is the CEO and president of C₂N Diagnostics, a specialty diagnostics company with a vision to bring Clarity Through Innovation®. The company’s Precivity™ tests are innovative new blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease, and aid in medical management and treatment decisions.
Listen Live or Listen at Your Convenience Tuesday, November 21st, 2023 2 pm EST, 1 pm CST, 12 pm MST, 11 am PST & 7 pm London GMT, 9 pm South Africa SAST, and on the 22nd at 6 am in Australia AEDT
Learn:
- What is C2N Diagnostics working on?
- What are the 3 types of Precivity tests?
- How fast do the blood tests get turned around for results?
- Are all Precivity tests needed?
- Is genetic counseling set up as support for those taking the APOE tests?
- What is the cost-effectiveness of the Precivity tests compared to other tests such as MRIs and PET Scans?
- Is there a financial assistance program for the Precivity tests?